FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma

Journal of Clinical Investigation

Volumn 119, Issue 5, 2009, Pages 1077-1079

  Hadari, Yaron ^a   Schlessinger, Joseph ^b  

^a Kolltan Pharmaceuticals   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY R3; MUTANT PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; FGFR3 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CRYSTAL STRUCTURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; IN VITRO STUDY; MULTIPLE MYELOMA; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR MODEL; XENOGRAFT; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN ANTIBODY COMPLEX; BIOLOGICAL MODEL; BLADDER TUMOR; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG SCREENING; IMMUNOLOGY; METABOLISM; MOUSE; PATHOLOGY; PROTEIN BINDING; PROTEIN CONFORMATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGEN-ANTIBODY COMPLEX; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MICE; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MULTIPLE MYELOMA; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RNA INTERFERENCE; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66449083374     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI38948     Document Type: Note

References (12)

1. Eswarakumar, V.P., Lax, I., and Schlessinger, J. 2005. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 16:139-149.
2. Dailey, L., Ambrosetti, D., Mansukhani, A., and Basilico, C. 2005. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev. 16:233-247.
3. Chesi, M., et al. 1997. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet. 16:260-264.
4. Knowles, M.A. 2008. Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors. Future Oncol. 4:71-83.
5. Trudel, S., et al. 2004. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood. 105:2941-2948.
6. Grand, E.K., Chase, A.J., Heath, C., Rahemtulla, A., and Cross, N.C. 2004. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia. 18:962-966.
7. Qing, J., et al. 2009. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J. Clin. Invest. 119:1216-1229.
8. Plotnikov, A.N., Schlessinger, J., Hubbard, S.R., and Mohammadi, M. 1999. Structural basis for FGF receptor dimerization and activation. Cell. 98:641-650.
9. Schlessinger, J., et al. 2000. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell. 6:743-750.
10. Chen, L., et al. 1999. Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis. J. Clin. Invest. 104:1517-1525.
11. Twigg, S.R., et al. 2009. Skeletal analysis of the Fgfr3(P244R) mouse, a genetic model for the Muenke craniosynostosis syndrome. Dev. Dyn. 238:331-342.
12. Pannier, S., et al. 2009. Activating Fgfr3 Y367C mutation causes hearing loss and inner ear defect in a mouse model of chondrodysplasia. Biochim. Biophys. Acta. 2:140-147.